NASDAQ:KALA - Kala Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $7.50
  • Forecasted Upside: 621.15 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$1.04
▼ -0.01 (-0.95%)

This chart shows the closing price for KALA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Kala Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for KALA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for KALA

Analyst Price Target is $7.50
▲ +621.15% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Kala Pharmaceuticals in the last 3 months. The average price target is $7.50, with a high forecast of $9.00 and a low forecast of $6.00. The average price target represents a 621.15% upside from the last price of $1.04.

This chart shows the closing price for KALA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 contributing investment analysts is to buy stock in Kala Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/26/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/24/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/22/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/22/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/21/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/19/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/18/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/17/2022

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/15/2021WedbushReiterated RatingOutperformHigh
11/16/2021Northland SecuritiesLower Price TargetOutperform$12.00 ➝ $6.00Low
11/16/2021HC WainwrightLower Price TargetBuy$11.00 ➝ $9.00Low
10/21/2021HC WainwrightReiterated RatingBuy$11.00Low
8/6/2021HC WainwrightLower Price TargetBuy$14.00 ➝ $11.00Medium
8/6/2021JPMorgan Chase & Co.DowngradeOverweight ➝ NeutralMedium
6/4/2021HC WainwrightReiterated RatingBuy$14.00High
5/12/2021HC WainwrightLower Price TargetBuy$16.00 ➝ $14.00Low
5/6/2021HC WainwrightReiterated RatingBuy$16.00 ➝ $14.00High
2/17/2021HC WainwrightReiterated RatingBuy$17.00Low
11/30/2020Northland SecuritiesReiterated RatingBuy$17.00Low
10/28/2020WedbushBoost Price TargetOutperform$39.00 ➝ $47.00High
10/5/2020WedbushReiterated RatingBuy$39.00Low
9/14/2020Jefferies Financial GroupDowngradeBuy ➝ Hold$21.00 ➝ $10.00High
8/18/2020WedbushReiterated RatingBuy$39.00High
8/7/2020Northland SecuritiesReiterated RatingBuy$17.00High
8/4/2020WedbushReiterated RatingBuy$39.00Medium
7/23/2020Northland SecuritiesInitiated CoverageOutperform$17.00Low
6/14/2020WedbushReiterated RatingBuy$39.00High
6/2/2020WedbushReiterated RatingBuy$39.00High
5/29/2020OppenheimerInitiated CoverageOutperform$16.00 ➝ $21.00High
5/27/2020JPMorgan Chase & Co.Boost Price TargetOverweight$14.00 ➝ $19.00High
5/27/2020HC WainwrightReiterated RatingBuy$14.00 ➝ $17.00High
5/11/2020WedbushReiterated RatingBuy$35.00High
5/8/2020HC WainwrightBoost Price TargetBuy$13.00 ➝ $14.00High
5/4/2020WedbushReiterated RatingBuy$34.00Low
4/22/2020WedbushReiterated RatingBuy$34.00Low
4/13/2020HC WainwrightReiterated RatingBuy$13.00High
3/29/2020WedbushReiterated RatingBuy$34.00Low
3/18/2020HC WainwrightBoost Price TargetBuy$10.00 ➝ $13.00Low
3/17/2020WedbushReiterated RatingBuy$34.00Low
3/10/2020OppenheimerBoost Price TargetOutperform$13.00 ➝ $16.00High
3/10/2020WedbushBoost Price TargetOutperform$51.00 ➝ $52.00High
3/9/2020Bank of AmericaUpgradeNeutral ➝ Buy$15.00High
3/9/2020WedbushReiterated RatingBuy$51.00High
2/12/2020WedbushReiterated RatingBuy$51.00High
1/21/2020HC WainwrightReiterated RatingBuy$10.00High
12/23/2019WedbushReiterated RatingBuy$51.00Medium
12/17/2019Bank of AmericaDowngradeBuy ➝ Neutral$9.00 ➝ $6.00High
11/11/2019HC WainwrightReiterated RatingBuy$12.00 ➝ $10.00High
8/7/2019OppenheimerSet Price TargetBuy$9.00High
8/7/2019WedbushReiterated RatingOutperform$51.00High
8/7/2019HC WainwrightLower Price TargetBuy$15.00 ➝ $12.00High
7/5/2019WedbushSet Price TargetBuy$51.00Low
5/14/2019WedbushSet Price TargetBuy$51.00Low
4/24/2019OppenheimerInitiated CoverageOutperform$11.00 ➝ $11.00Low
3/14/2019Jefferies Financial GroupInitiated CoverageBuy$15.00High
1/16/2019WedbushSet Price TargetBuy$51.00High
12/27/2018HC WainwrightReiterated RatingBuy$15.00High
11/14/2018JPMorgan Chase & Co.Lower Price TargetOverweight ➝ Overweight$35.00 ➝ $22.00Low
11/9/2018HC WainwrightSet Price TargetBuy$15.00High
10/17/2018HC WainwrightSet Price TargetBuy$32.00Low
10/16/2018WedbushSet Price TargetBuy$51.00Low
10/10/2018WedbushSet Price TargetBuy$51.00Medium
10/4/2018HC WainwrightReiterated RatingBuy$32.00Low
10/4/2018Wells Fargo & CompanyReiterated RatingBuy$19.00 ➝ $15.00Low
9/10/2018HC WainwrightSet Price TargetBuy$37.00Low
8/26/2018WedbushSet Price TargetBuy$51.00Medium
8/24/2018HC WainwrightBoost Price TargetBuy ➝ Buy$35.00 ➝ $37.00Medium
8/23/2018Wells Fargo & CompanyReiterated RatingBuyMedium
8/16/2018HC WainwrightSet Price TargetBuy$35.00High
8/15/2018Wells Fargo & CompanySet Price TargetBuy$19.00High
8/10/2018HC WainwrightSet Price TargetBuy$35.00Low
8/9/2018WedbushSet Price TargetBuy$47.00Medium
8/1/2018HC WainwrightSet Price TargetBuy$35.00Low
7/23/2018HC WainwrightInitiated CoverageBuy$35.00High
6/20/2018WedbushReiterated RatingOutperform$47.00High
5/15/2018WedbushLower Price TargetOutperform$47.00 ➝ $46.00Low
1/25/2018Wells Fargo & CompanyReiterated RatingOutperform ➝ Outperform$24.00 ➝ $19.00Medium
1/5/2018Wells Fargo & CompanyReiterated RatingBuyHigh
12/22/2017WedbushReiterated RatingOutperform$46.00Medium
11/30/2017WedbushReiterated RatingBuy$46.00Medium
11/19/2017JPMorgan Chase & Co.Set Price TargetBuy$35.00N/A
10/19/2017WedbushReiterated RatingOutperform$46.00N/A
8/15/2017OppenheimerInitiated CoverageOutperform ➝ Outperform$46.00 ➝ $46.00Low
8/14/2017Bank of AmericaInitiated CoverageBuy ➝ Buy$33.00High
8/14/2017Wells Fargo & CompanyInitiated CoverageOutperform$24.00High
8/14/2017WedbushInitiated CoverageOutperform ➝ Outperform$46.00High
8/14/2017JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$35.00High
(Data available from 1/18/2017 forward)

News Sentiment Rating

0.26 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/22/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/22/2021
  • 3 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
8/21/2021
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/20/2021
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/20/2021
  • 5 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/19/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/19/2021
  • 1 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/18/2022

Current Sentiment

  • 1 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Kala Pharmaceuticals logo
Kala Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based Mucus Penetrating Particles, or MPP, technology, with an initial focus on the treatment of eye diseases. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Watertown, MA.
Read More

Today's Range

Now: $1.04
Low: $1.00
High: $1.05

50 Day Range

MA: $1.54
Low: $1.02
High: $2.16

52 Week Range

Now: $1.04
Low: $1.00
High: $9.97

Volume

542,103 shs

Average Volume

994,230 shs

Market Capitalization

$68.12 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.23

Frequently Asked Questions

What sell-side analysts currently cover shares of Kala Pharmaceuticals?

The following sell-side analysts have issued stock ratings on Kala Pharmaceuticals in the last year: HC Wainwright, JPMorgan Chase & Co., Northland Securities, Wedbush, and Zacks Investment Research.
View the latest analyst ratings for KALA.

What is the current price target for Kala Pharmaceuticals?

2 Wall Street analysts have set twelve-month price targets for Kala Pharmaceuticals in the last year. Their average twelve-month price target is $7.50, suggesting a possible upside of 621.2%. HC Wainwright has the highest price target set, predicting KALA will reach $9.00 in the next twelve months. Northland Securities has the lowest price target set, forecasting a price of $6.00 for Kala Pharmaceuticals in the next year.
View the latest price targets for KALA.

What is the current consensus analyst rating for Kala Pharmaceuticals?

Kala Pharmaceuticals currently has 1 hold rating and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe KALA will outperform the market and that investors should add to their positions of Kala Pharmaceuticals.
View the latest ratings for KALA.

How do I contact Kala Pharmaceuticals' investor relations team?

Kala Pharmaceuticals' physical mailing address is 490 ARSENAL WAY SUITE 120, WATERTOWN MA, 02472. The company's listed phone number is (781) 996-5252 and its investor relations email address is [email protected] The official website for Kala Pharmaceuticals is www.kalarx.com.